Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Administration and Policy in Mental Health and Mental Health Services Research
Erschienen in: Administration and Policy in Mental Health and Mental Health Services Research 3/2007

01.05.2007 | Original Paper

The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia

verfasst von: Marion A. Becker, M. Scott Young, Ezra Ochshorn, Ronald J. Diamond

Erschienen in: Administration and Policy in Mental Health and Mental Health Services Research | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

While some studies show a significant advantage in adherence rates with use of atypical versus typical antipsychotic medication, others show no advantage or mixed results (Jones et al. (2006). Archives of General Psychiatry, 63, 1079–1087; Rosenheck, (2006). Archives of General Psychiatry, 63, 1074–1076). This study examined treatment outcomes and costs associated with adherence rates by antipsychotic medication class for adult Medicaid beneficiaries in Florida diagnosed with schizophrenia. Outcomes examined include arrests, involuntary commitments, and physical and behavioral healthcare costs. Study findings demonstrate that medication adherence for persons with schizophrenia may be as important to treatment costs and benefits as the class of medication used.
Literatur
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005). Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry, 162, 441–449.PubMedCrossRef
Awad, A. G., & Voruganti, L. N. (2004). New antipsychotics, compliance, quality of life, and subjective tolerability—Are patients better off? Canadian Journal of Psychiatry, 49(5), 297–302.
Baker, F. M., & Bell, C. (1999). Issues in the psychiatric treatment of African Americans. Psychiatric Services, 50(3), 362–350.PubMed
Becker, M., & Diamond, R. (2005). Quality of life measurement in persons with schizophrenia: Are we measuring what’s important? In H. Katschnig & H. Freeman (Eds.), Quality of life in mental disorders (2nd ed.). Chichester, England: Wiley.
Becker, M., Jang, Y., & Kane, M. (2006). Evaluation of Florida Medicaid behavioral health pharmacy practice by racial/ethnic minorities across the lifespan (pp. 1–27). Tampa, FL: Louis de la Parte Florida Mental Health Institute, University of South Florida.
Becker, M., & Lemrow, N. (2004). Behavioral health care services associated with switching atypical antipsychotic medication for persons with SMI (pp. 1–76). Tampa, FL: Louis de la Parte Florida Mental Health Institute, University of South Florida.
Boyd, D. L. (2003). The bursting State Fiscal Bubble and State Medical Budgets. Health Affairs, 22(1), 46–61.PubMedCrossRef
Brown, C., Markowitz, J., Moore, T., & Parker, N. (1999). Atypical antipsychotics, part II: Adverse effects, drug interactions, and costs. Annals of Pharmacotherapy, 33, 210–217.PubMedCrossRef
Csernansky, J. G., & Schuchart, E. K. (2002). Relapse and rehospitalisation rates in patients with schizophrenia: Effects of second generation antipsychotics. CNS Drugs, 16, 473–484.PubMedCrossRef
Daumit, G. L., Crum, R. M., Guallar, E., et al. (2003). Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and Whites in the United States. Archives of General Psychiatry, 60, 121–128.PubMedCrossRef
Davis, J. M., Chen, N., & Glick, I. D. (2003). A meta-analysis of the efficacy of second generation antipsychotics. Archive of General Psychiatry, 60, 553–564.CrossRef
Dolder, C. R., Lacro, J. P., Dunn, L. B., et al. (2002). Antipsychotic medication adherence: Is there a difference between typical and atypical agents? American Journal of Psychiatry, 159, 103–108.PubMedCrossRef
Dolder, C. R., Lacro, J. P., & Jeste, D. V. (2003). Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosomatic Medicine, 65, 156–162.PubMedCrossRef
Eaddy, M., Grogg, A., & Locklear, J. (2005). Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clinical Therapeutic, 27(2), 263–272.CrossRef
Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997). Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23(4), 637–651.PubMed
Fichtner, C. G., Hanrahan, P., & Luchins, D. J. (1998). Pharmacoeconomic studies of atypical antipsychotics: Review and perspective. Psychiatric Annals, 28(7), 381–396.
Foster, R. H., & Goa, K. L. (1999). Olanzapine: A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics, 15, 611–640.PubMedCrossRef
Gardner, J. C., Luo, Z., Bradley, C. J., Polverrjan, E., Holmes-Rovnes, M., & Rovner, D. (2003). Longitudinal assessment of cost in health care intervention. Health Services Research Methodology, 3, 149–168.CrossRef
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000). Atypical antipsychotics in treatment of schizophrenia: Systematic overview and meta-regression analysis. British Nursing Journal, 321, 1371–1376.
Gibson, J., Damler, R., Jackson, A. E., Wilder, T., & Ramsey, J. L. (2004). The impact of olanzapine, risperidone, or haldol on the cost of schizophrenia care in a Medicaid population. Value in Health, 7(1), 22–35.PubMedCrossRef
Glazer, W. M. (1998). Formulary decisions and health economics. Journal of Clinical Psychiatry, 59(Suppl. 19), 23–29.PubMed
Hargraves, W. A., & Shumway, M. (1996). Pharmacoeconomics of antipsychotic drug therapy. Journal of Clinical Psychiatry, 57(Suppl. 9), 66–76.
Haynes, R. B. (1979). Introduction. In R. B. Haynes, D. L. Sackett, & D. W. Taylor (Eds.), Compliance in health care (pp. 1–10). Baltimore, MD: John Hopkins University Press.
Herbeck, D. M., West, J. C., Ruditis, I., et al. (2004). Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatric Services, 55, 677–684.PubMedCrossRef
Hogan, M. F. (1999). Public-sector mental health care: New challenges. Health Affairs, 18, 106–111.PubMedCrossRef
Javaid, J. I., Holland, D., & Janicak, P. G. (1991). Blood level monitoring of antipsychotics and antidepressants. Psychiatric Medicine, 9(1), 163–187.PubMed
Jones, K., Chen, H. J., Jordan, N., Boothroyd, R. A., Ramoni-Perazzi, J., & Shern, D. L. (2006). Examination of formal treatment costs in the provision of managed care for a Medicaid population with psychiatric disabilities. Medical Care, 44, 320–327.PubMedCrossRef
Jones, P., Barnew, T., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K., Murray, R., Markwick, A., & Lewis, S. (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry, 63, 1079–1087.PubMedCrossRef
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry, 63(10), 892–909.PubMed
Lehman, A. F., & Steinwachs, D. M. (1998). Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1–10.PubMed
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R., Perkins, D., Keefe, R., Davis, S., Davis, C., Lebowitz, B., Severe, J., & Hsiano, J. (2005). Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with schizophrenia. New England Journal of Medicine, 353, 1209–1223.PubMedCrossRef
McCombs, J. S., Nichol, M. B., Johnstone, B. M., Stimmel, G. L., Shi, J., & Smith, R. (2000). Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatric Services, 51(4), 525–527.PubMedCrossRef
Mojtabai, R., Lavelle, J., Gibson, P.J., et al. (2002). Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989–1996. Psychiatric Services, 53(3), 337–339.PubMedCrossRef
Moy, E., Dayton, E., & Clancy, C. M. (2005). Compiling the evidence: The national healthcare disparities reports. Public Response, March/April, pp. 376–386.
Naber, D., Moritz, S., Lambert, M., et al. (2001). Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophrenia Research, 50, 79–88.PubMedCrossRef
Nicole, L. (2005). Health disparities—Less talk more action. New England Journal of Medicine, 35(7), 727–729.
Olivieri, N., Matsui, D., Hermann, C., & Koren, G. (1991). Compliance assessed by the medication event monitoring system. Archives of Disease in Childhood, 66, 1399–1402.PubMedCrossRef
Pandiana, J. A., & Banks, S. M. (2003). Large data sets are powerful. Psychiatric Services, 54, 745.CrossRef
Ren, X. S., Kazia, L. E., Lee, A. F., et al. (2002). Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. Journal of Pharmacy and Therapeutics, 27, 441–451.CrossRef
Rice, D. P. (1999). The economic impact of schizophrenia. Journal of Clinical Psychiatry, 60(Suppl. 1), 4–6.PubMed
Rittmannsberger, H., Pachinger, T., Keppelmuller, P., & Wancata, J. (2004). Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatric Services, 55(2), 174–179.PubMedCrossRef
Rosenheck, R. (2006). Outcomes, costs, and policy caution: A commentary on the cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry, 63, 1074–1076.PubMedCrossRef
Rosenheck, R., Perlick, D., Bingham, S., et al. (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association, 290(20), 2693–2702.PubMedCrossRef
Schneider, E. C., Zaslavsky, A. M., & Epstein, A. M. (2002). Racial disparities in the quality of care for enrollees in medicare managed care. Journal of the American Medical Association, 287(10), 1288–1294.PubMedCrossRef
Shern, D., Robinson, P., Giard, J., & Vargo, A., et al. (2005). Evaluation of Florida’s Medicaid Managed Mental Health Plans: Year 8 Report Tampa, FL: Louis de la Parte Florida Mental Health Institute, University of South Florida.
Svarstad, B. L., Shireman, T. I., & Sweeney, J. K. (2001). Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services, 52, 805–811.PubMedCrossRef
Tandon, R. (1998). In conclusion, does antipsychotic treatment modify the long-term course of schizophrenic illness? Journal of Psychiatric Research, 32, 251–253.PubMedCrossRef
Thieda, P., Beard, S., Richter, A., & Kane, J. (2003). An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatric Services, 54(4), 508–516.PubMedCrossRef
Valenstein, M., Blow, F. C., Copeland, L. A., Mcarthy, J. F., et al. (2004). Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors. Schizophrenia Bulletin, 30(2), 255–264.PubMed
Vanelli, M., Burstein, P., & Crammer, J. (2001). Refill patterns of atypical and conventional antipsychotic medication at a national retail pharmacy chain. Psychiatric Services, 52, 1248–1250.PubMedCrossRef
Weiden, P., Aquila, R., & Standard, J. (1996). Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry, 57(Suppl. ll), 53–60.PubMed
Weiden, P. J., Kozma, C., Grogg, A., & Locklear, J. (2004). Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services, 55(8), 886–891.PubMedCrossRef
Weiden, P. J., & Olfson, M. (1995). Cost of relapse in schizophrenia. Schizophrenia Bulletin, 21, 419–429.PubMed
Weiden, P., & Zygmunt, A. (1997). Medication noncompliance in schizophrenia. Part I. Assessment. Journal of Practical Psychiatry and Behavioral Health, 3, 106–110.
Wyatt, R. J., Henter, I., Leary, M. C., & Taylor, E. (1995). An economic evaluation of schizophrenia. Social Psychiatry and Psychiatric Epidemiology, 30, 196–205.PubMed
Ziguras, S. J., Klimidis, S., Lambert, T. J. R., & Jackson, A. C. (2001). Determinants of anti-psychotic medication compliance in a multicultural population. Community Mental Health Journal, 37(3), 273–283.PubMedCrossRef
Metadaten
Titel
The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia
verfasst von
Marion A. Becker
M. Scott Young
Ezra Ochshorn
Ronald J. Diamond
Publikationsdatum
01.05.2007
Erschienen in
Administration and Policy in Mental Health and Mental Health Services Research / Ausgabe 3/2007
Print ISSN: 0894-587X
Elektronische ISSN: 1573-3289
DOI
https://doi.org/10.1007/s10488-006-0108-5

Weitere Artikel der Ausgabe 3/2007

Administration and Policy in Mental Health and Mental Health Services Research 3/2007 Zur Ausgabe

Original Paper

Empirical Evaluation of the Generalizability of the Sample from the Multimodal Treatment Study for ADHD

Original Paper

Developing Strategies to Integrate Peer Providers into the Staff of Mental Health Agencies

Original Paper

A Competency-Based Approach to Managing Violence with Involuntary Outpatient Treatment

Original Paper

A Crisis of Credibility: Professionals’ Concerns about the Psychiatric Care Provided to Clients of the Child Welfare System

Original Paper

Rurality and Mental Health Treatment

Original Paper

Administrative Barriers to the Adoption of High-Quality Mental Health Services for Children in Foster Care: A National Study

Neu im Fachgebiet Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise